Suda Pharmaceuticals and Sanofi-Aventis Groupe signed an agreement under which Sanofi will fully fund a feasibility study by Suda of one of its active ingredients, using Suda’s OroMist Technology.
The feasibility study is expected to be completed by March 31, 2021.
Suda and Sanofi have not mentioned the name of the active ingredient on which the feasibility study will be carryout out.
Suda operates in the field of development of oro-mucosal drug administration. It creates versions of existing drugs that be ingested from the mouth via a pump or spray. Drugs delivered through the oral cavity are more quickly absorbed than those delivered through the digestive tract as there is a high concentration of blood vessels in the tongue, cheeks, palate, and gums.
Drug absorption through the digestive tract is also affected by different foods and the presence or absence of enzymes in the stomach. It is not the case with oral absorption.
Suda has developed Zolpimist, a US FDA approved patented oro-mucosal spray treatment for insomnia. It is currently working to develop oro-mucosal versions of the following medicines.
- ArTiMist for malaria.
- Ondansetron for nausea.
- Sildenafil for erectile dysfunction.
- Midazolam for Epileptic and anxiety.
- Anagrelide for cancer.
- Sumatriptan for migraine
- Cannabinoids (CBD)
Sanofi is a pharmaceutical firm with a presence in over 100 countries. It operates in various areas like general medicines, vaccines, etc. It also develops drugs for rare diseases.
